The phase III ShortHER trial compared the efficacy of different durations of trastuzumab therapy for patients with HER2-positive breast cancer. Long-term results were recently published by Conte et al in the Journal of Clinical Oncology.
Question 1 of 5
What was the 10-year overall survival rate for patients receiving the 9-week trastuzumab regimen compared to the 1-year regimen?
